2026 Volume: 02 Issue: 02 www.ijrpa.com ISSN 2456-9995 Review Article

International Journal Research Publication Analysis

Page: 01-13

HARNESSING ARTIFICIAL INTELLIGENCE AND PREDICTIVE ALGORITHMS FOR CLINICAL DECISION SUPPORT IN TYPE 2 DIABETES MANAGEMENT: A SYSTEMATIC REVIEW AND FUTURE PERSPECTIVES

[*1]Er. Sangeeta Lalwani, [2]Er. Harshit Gupta

[1]Assistant Professor, Department of Computer Science & Engineering, Rajshree Institute of Management & Technology, Bareilly (U.P.), India.

[2]Assistant Professor, Department of Computer Science & Engineering, Rajshree Institute of Management & Technology, Bareilly (U.P.), India.

Article Received: 25 December 2025
Article Revised: 14 January 2026
Published on: 03 February 2026

***Corresponding Author: Er. Sangeeta Lalwani**
Assistant Professor, Department of Computer Science & Engineering, Rajshree Institute of Management & Technology, Bareilly (U.P.), India.

DOI: https://doi-doi.org/101555/ijrpa.8151

ABSTRACT

Type 2 Diabetes (T2D) represents a global health crisis of unparalleled scale, characterized by its rising prevalence, significant morbidity, and substantial economic burden. The inherent complexity of T2D management, which requires continuous monitoring and multifaceted intervention, often strains traditional healthcare models, leading to therapeutic inertia and suboptimal outcomes. Clinical Decision Support Systems (CDSS) have emerged as a promising tool to augment clinical practice, yet their early iterations were limited by static, rule-based architectures. The integration of Artificial Intelligence (AI) and predictive algorithms is catalyzing a paradigm shift, transforming CDSS from simple alerting mechanisms into dynamic, data-driven, and personalized intelligent assistants. This paper provides a comprehensive review of the application of AI-powered CDSS in T2D management. We begin by outlining the clinical and operational challenges of T2D that necessitate advanced decision support. We then trace the evolution of CDSS and delve into the technical foundations of relevant AI and machine learning (ML) methodologies, including supervised, unsupervised, and deep learning approaches. The core of the paper synthesizes current applications across four key domains: (1) predictive risk stratification for disease onset and complications; (2) personalized glycemic control and treatment optimization; (3) early and automated detection of diabetes-related complications; and (4) enhancement of

patient engagement and self-management. A critical analysis of the significant challenges hindering widespread clinical adoption is presented, encompassing data quality issues, algorithmic bias, the "black box" problem of interpretability, workflow integration, and regulatory/ethical considerations. Finally, we explore promising future directions, including federated learning, causal AI, and the concept of digital twins, and conclude with recommendations for researchers, clinicians, and policymakers to responsibly translate this transformative technology into improved, equitable, and person-centered diabetes care.

KEYWORDS: Clinical Decision Support, Type 2 Diabetes, Artificial Intelligence, Machine Learning, Predictive Modeling, Personalized Medicine, Algorithmic Bias, Explainable AI.

1. INTRODUCTION

The 21st century is witness to a global pandemic of a different sort: Type 2 Diabetes (T2D). Affecting an estimated 537 million adults worldwide, a figure projected to rise to 643 million by 2030, T2D imposes a devastating toll on individuals and healthcare systems alike (International Diabetes Federation, 2021). The disease is the leading cause of blindness, end-stage renal disease, and non-traumatic lower-limb amputation, and it significantly elevates the risk of cardiovascular disease, the primary cause of mortality in this population. Beyond the human cost, the economic burden is staggering, with global healthcare expenditures on diabetes exceeding $966 billion in 2021 (IDF, 2021). The management of T2D is intrinsically complex, extending far beyond simple glucose-lowering. It requires a holistic, continuous approach addressing glycemic control, blood pressure, lipid levels, lifestyle modification, and the prevention or management of multiple co-morbidities.

Traditional clinical practice, often guided by generalized, evidence-based guidelines, struggles to keep pace with the individual variability of each patient's disease trajectory, physiology, and lifestyle. This complexity frequently leads to "clinical inertia," the failure to intensify therapy when clinically indicated, resulting in prolonged periods of poor glycemic control and accelerated development of irreversible complications (Phillips et al., 2001). Furthermore, the sheer volume of patient data—from electronic health records (EHRs), laboratory results, and continuous glucose monitors (CGMs)—presents a cognitive overload for clinicians, making it difficult to identify subtle patterns and predict future risks.

Clinical Decision Support Systems (CDSS) were introduced to bridge this gap. These are computer systems designed to assist clinicians with decision-making tasks. Early CDSS were predominantly rule-based, operating on IF-THEN logic derived from clinical guidelines (e.g.,

"IF HbA1c > 8% on metformin, THEN add a second agent"). While useful, these systems are static, lack personalization, and their incessant, often contextually irrelevant, alerts contribute to "alert fatigue," a well-documented cause of user non-compliance (Van Der Sijs, Aarts, Vulto, & Berg, 2006).

The advent of Artificial Intelligence (AI) and its subfield of machine learning (ML) offers a profound opportunity to overcome the limitations of traditional CDSS. By leveraging vast datasets, AI-powered predictive algorithms can uncover complex, non-linear relationships within patient data, forecast future clinical events, and generate patient-specific recommendations that adapt over time. These systems can move from reactive, guideline-based reminders to proactive, predictive, and personalized support, heralding a new era of precision medicine for T2D. This paper will provide a detailed, academic review of the current state, applications, challenges, and future horizons of AI-driven CDSS for the management of Type 2 Diabetes. We posit that the responsible integration of these technologies is not merely an incremental improvement but a fundamental transformation in the delivery of diabetes care.

2. The Burden and Complexity of Type 2 Diabetes Management

To fully appreciate the potential of AI in this domain, one must first understand the multifaceted challenges inherent in T2D care. The pathophysiology of T2D, characterized by progressive insulin resistance and beta-cell dysfunction, is itself heterogeneous. Patients present with varying degrees of insulin deficiency and resistance, different body compositions, and diverse genetic predispositions. This biological heterogeneity means that a one-size-fits-all therapeutic approach is inherently suboptimal.

Clinical management is a continuous balancing act. Tight glycemic control is paramount for preventing microvascular complications (retinopathy, nephropathy, neuropathy), but overly aggressive control can lead to hypoglycemia, which is associated with acute adverse events, cardiovascular mortality, and significant impairment in quality of life (Cryer, 2012). Clinicians must navigate a rapidly expanding therapeutic landscape, with over ten classes of glucose-lowering agents, each with a distinct efficacy, safety profile, and mechanism of action. Recent advances have shifted focus from simply lowering glucose to considering weight effects, cardiovascular and renal benefits, and hypoglycemia risk. Selecting the right drug for the right patient at the right time is a complex decision that requires synthesizing a vast array of patient-specific information.

Beyond glycemia, comprehensive diabetes care involves aggressive management of blood pressure and lipids to mitigate macrovascular risk (myocardial infarction, stroke). This necessitates polypharmacy, which increases the risk of drug-drug interactions and adverse effects, further complicating the therapeutic regimen. A critical, and often underestimated, component is lifestyle. Diet, physical activity, and sleep have profound impacts on glycemia and overall health, yet modifying patient behavior is notoriously difficult. Clinicians are often ill-equipped to provide the intensive, ongoing counseling required, and adherence to lifestyle recommendations is notoriously poor.

These challenges converge to create the problem of therapeutic inertia. Studies show that a significant proportion of patients remain above their glycemic targets for years before therapy is intensified (Zafar, Stone, & Davies, 2021). This latency exacerbates the risk of complications and underscores the urgent need for tools that can provide more timely, data-driven, and actionable insights to empower both clinicians and patients.

3. The Evolution of Clinical Decision Support Systems

CDSS have evolved significantly since their inception in the 1970s. Understanding this evolution provides context for the AI-driven transformation currently underway.

3.1. Rule-Based Systems: The first generation of CDSS were primarily knowledge-based, employing logic rules derived from clinical practice guidelines and expert consensus. A typical system might flag an abnormally high creatinine level or suggest a screening test based on a patient's age and diagnosis. While instrumental in standardizing certain aspects of care, these systems suffer from critical limitations. Their rigidity means they cannot adapt to the nuances of individual patient contexts. For example, a rule to intensify insulin for a high HbA1c might be inappropriate for an elderly patient with frequent hypoglycemia. These systems also require manual updates as guidelines change, making them quickly outdated.

3.2. Data-Driven Systems: The proliferation of EHRs in the late 20th and early 21st centuries provided the substrate for a new generation of data-driven CDSS. These systems used statistical models on historical patient data to provide more sophisticated support, such as estimating a patient's risk of readmission. However, these early models were still often based on linear regression and similar techniques that could not capture the full complexity of clinical data.

3.3. The AI-Aaugmented Era: The current era is defined by the integration of AI and ML. Unlike rule-based systems, ML models *learn* patterns directly from data without being explicitly programmed. This allows them to identify high-dimensional interactions between

variables that are imperceptible to human observers. An AI-augmented CDSS is not just an alert generator; it is a predictive engine. It might forecast the probability of a patient progressing to chronic kidney disease within the next five years, predict their glycemic response to a GLP-1 receptor agonist versus an SGLT2 inhibitor, or identify a subgroup of patients who would benefit most from a specific dietary intervention. This shift from static knowledge to dynamic learning is the cornerstone of the modern, intelligent CDSS.

4. Artificial Intelligence and Predictive Algorithms: The Technical Foundation

The power of AI-powered CDSS stems from a diverse toolkit of machine learning algorithms. The choice of algorithm depends on the clinical question, the nature of the available data, and the desired outcome.

4.1. Supervised Learning: This is the most common paradigm in clinical AI. Models are trained on a labeled dataset, where each data point has a known outcome. The goal is to learn a mapping function that can predict the outcome for new, unseen data.

- **Classification Models:** Used for predicting discrete categories.
  - **Logistic Regression:** A simple, interpretable model for binary outcomes (e.g., will/will not develop retinopathy).
  - **Support Vector Machines (SVMs):** Effective at finding complex boundaries between classes in high-dimensional space.
  - **Random Forests and Gradient Boosting Machines (e.g., XGBoost, LightGBM):** Ensemble methods that combine many decision trees to achieve high predictive accuracy. They are currently state-of-the-art for many structured EHR-based prediction tasks, such as risk stratification for cardiovascular events or hospitalization.
- **Regression Models:** Used for predicting a continuous value.
  - **Linear Regression:** Predicts values like future HbA1c or eGFR.
  - **Neural Networks (NNs):** Can model highly complex, non-linear relationships for both classification and regression tasks.

4.2. Unsupervised Learning: Used for exploring data without predefined labels. The goal is to discover hidden patterns or structures.

- **Clustering Algorithms (e.g., K-Means, Hierarchical Clustering):** These are powerful for discovering patient subgroups or phenotypes. For instance, clustering has been used to identify distinct T2D clusters, such as "severe insulin-deficient diabetes," "severe insulin-resistant diabetes," and "mild obesity-related diabetes," each with a different risk profile

and potentially different treatment needs (Ahlqvist et al., 2018). This moves towards a more granular, personalized classification of the disease.

4.3. Deep Learning: A subfield of ML based on artificial neural networks with many layers ("deep" architectures). Deep learning excels at handling complex, unstructured data.

- **Recurrent Neural Networks (RNNs) and Long Short-Term Memory (LSTM):** Specifically designed to handle sequential or time-series data. They are ideal for analyzing data from CGMs, which provide a dense stream of glucose readings. RNNs can predict future glucose levels and detect patterns preceding hypoglycemic or hyperglycemic events, enabling proactive management.
- **Convolutional Neural Networks (CNNs):** The architecture of choice for image analysis. They have achieved expert-level performance in detecting diabetic retinopathy from retinal fundus photographs, often with superior speed and consistency (Gulshan et al., 2016).

4.4. Data Sources for AI Algorithms: The performance of these models is critically dependent on the quality and breadth of the data used for training and validation. Key data sources include:

- **Electronic Health Records (EHRs):** The most common source, containing structured data (vitals, lab results, diagnoses, medications) and unstructured data (clinical notes).
- **Continuous Glucose Monitoring (CGM) and Insulin Pumps:** High-frequency, time-series data providing a rich picture of glycemic dynamics.
- **Wearable Devices:** Data on physical activity, sleep, and heart rate, offering crucial lifestyle context.
- **Patient-Reported Outcomes (PROs):** Data on diet, well-being, and medication adherence collected via surveys or apps.
- **"Omics" Data:** Genomic, proteomic, and metabolomic data, which hold the key to understanding individual disease predispositions and drug responses.

5. Applications of AI-Powered CDS for Type 2 Diabetes

AI-driven predictive algorithms are being applied across the entire spectrum of T2D care, from prevention to complication management.

5.1. Predictive Risk Stratification The most mature application of AI in this field is risk prediction.

- **Risk of Onset:** ML models trained on large EHR datasets can identify individuals with pre-diabetes who are at the highest risk of progressing to T2D. These models often incorporate a wider range of variables than traditional risk scores (like age, BMI, family history), including medication use, comorbidities, and even subtle patterns from clinical notes extracted via natural language processing (NLP). This allows for targeted allocation of intensive lifestyle intervention programs to those who would benefit most.
- **Risk of Complications:** This is a critical area for preventing morbidity.
  - **Cardiovascular Disease:** Gradient boosting models using EHR data have demonstrated superior performance over traditional scores like the Framingham Risk Score in predicting major adverse cardiovascular events (MACE) in diabetic patients (Khera et al., 2021). These models can identify high-risk patients who would be prime candidates for early initiation of SGLT2 inhibitors or GLP-1 receptor agonists, which have proven cardioprotective benefits.
  - **Diabetic Nephropathy:** Time-series analysis of lab values (e.g., serum creatinine, eGFR, albumin-to-creatinine ratio) using RNNs or other sequence models can predict the trajectory of kidney function decline more accurately than a single data point, allowing for early referral to nephrology.
  - **Diabetic Retinopathy:** While CNNs are used for detection (see 5.3), risk models can predict which patients are most likely to develop vision-threatening retinopathy, optimizing screening intervals. Patients at low risk may need less frequent screening, reducing costs and patient burden, while high-risk patients receive more intensive monitoring.

5.2. Personalized Glycemic Control and Treatment Optimization This is arguably the most transformative application, moving from risk prediction to therapeutic recommendation.

- **Predicting Medication Response:** A central challenge is choosing the right second-line agent after metformin. ML models are being developed to predict an individual's HbA1c response, weight change, and side effect profile for different drug classes. By training on data from thousands of patients who have started various medications, these models can learn the characteristics (e.g., baseline BMI, HbA1c, renal function, genetic markers) that predict response to a GLP-1 RA versus an SGLT2 inhibitor versus a DPP-4 inhibitor. The output of a CDS could be a ranked list of potential treatments with an estimated probability of success for each patient.

- **Insulin Dosing Support:** For patients on insulin therapy, especially those using pumps, AI offers sophisticated decision support. Algorithms using RNNs can analyze CGM data, meal information (entered by the patient), and activity levels from wearables to predict future glucose excursions. This allows the system to recommend proactive basal rate adjustments or bolus correction factors, moving from reactive correction of hyperglycemia to proactive prevention. Systems like the DreaMed Advisor have shown in clinical trials to be on par with expert endocrinologists in suggesting insulin dose adjustments (Nimri et al., 2020).
- **Lifestyle Recommendation:** By integrating CGM data with food logs and activity trackers, AI systems can identify individualized triggers for hyperglycemia. A CDS could provide personalized feedback, such as "Your post-breakfast glucose levels tend to be highest after meals high in refined carbohydrates. Consider trying scrambled eggs with avocado instead of cereal," thereby making dietary advice more concrete and actionable.

5.3. Early Detection of Complications AI is automating and scaling the screening for diabetic complications.

- **Diabetic Retinopathy:** As mentioned, CNNs applied to retinal fundus photos can detect retinopathy with sensitivity and specificity exceeding 95%, comparable to retinal specialists (Gulshan et al., 2016). Integrated into a CDS workflow, such a system could automatically screen all imaging, flagging positive cases for urgent ophthalmologist review. This dramatically increases screening capacity, particularly in underserved areas where access to specialists is limited.
- **Diabetic Foot Ulcers:** Computer vision techniques are being developed to analyze images of patients' feet taken on a smartphone. These AI models can detect early signs of ulcers, calluses, or infections, prompting early clinical intervention and potentially preventing amputations.
- **Cardiac Autonomic Neuropathy:** ML models can analyze subtle changes in heart rate variability (HRV) from ECG or wearable data to detect early signs of cardiac autonomic neuropathy, a condition that is difficult to diagnose but carries a high risk of mortality.

5.4. Patient Engagement and Self-Management Support AI is extending the reach of the clinical team beyond the clinic walls.

- **AI Chatbots and Conversational Agents:** Intelligent chatbots powered by NLP can provide patients with 24/7 access to education about their condition, answer common

questions about diet and medication, and deliver motivational messages to encourage adherence.

- **Smart Mobile Applications:** The next generation of diabetes apps will be truly "intelligent." Connected to CGM, insulin pumps, and wearables, they will act as a personalized coach. They will analyze the user's data stream in real-time, offering context-aware alerts and advice, learning the user's patterns, and adapting its recommendations accordingly. This creates a continuous feedback loop that empowers patients to become more active participants in their own care.

6. CHALLENGES, LIMITATIONS, AND ETHICAL CONSIDERATIONS

Despite the immense promise, the path to routine clinical implementation of AI-powered CDSS is fraught with significant challenges that must be addressed.

6.1. Data Quality and "Garbage In, Garbage Out": The performance of any ML model is fundamentally constrained by the quality of the data it was trained on. EHR data is notoriously messy. It contains missing values, errors, inconsistencies in coding, and biases in how clinical information is documented. A model trained on poor-quality data will produce unreliable and potentially dangerous recommendations, a phenomenon encapsulated by the phrase "garbage in, garbage out." Robust data cleaning, preprocessing, and validation pipelines are essential but often underappreciated prerequisites.

6.2. Algorithmic Bias and Health Equity: This is perhaps the most critical ethical challenge. If a model is trained on data from a specific population (e.g., a majority academic medical center), it may learn spurious correlations related to race, socioeconomic status, or other demographic factors and perform poorly when applied to other groups. For example, a risk prediction model trained primarily on data from white patients may systematically underestimate risk in Black or Hispanic patients, thereby exacerbating existing health disparities. Ensuring that training datasets are diverse and representative, and that models are rigorously tested for fairness across different subpopulations, is a non-negotiable requirement for equitable deployment.

6.3. Interpretability and the "Black Box" Problem: Many of the most powerful ML models, such as deep neural networks and complex ensemble methods, operate as "black boxes." It can be difficult or impossible to understand *why* the model made a particular prediction. Clinicians are (and should be) reluctant to trust a recommendation if they cannot understand its reasoning. This lack of transparency is a major barrier to adoption. The emerging field of Explainable AI (XAI) aims to address this by developing techniques (e.g.,

SHAP, LIME) that can provide post-hoc explanations for model predictions, highlighting the most influential factors. For clinical use, a CDSS must not only provide a recommendation but also a clear, human-interpretable justification.

6.4. Integration into Clinical Workflow: A brilliant AI algorithm is useless if it does not fit seamlessly into the real-world clinical workflow. Poorly designed systems can increase cognitive load, disrupt clinical routines, and contribute to the very alert fatigue they were meant to solve. Successful CDS must be context-aware, presenting information at the right time and in the right format, and allowing for easy user interaction and override. This requires a co-design process involving clinicians, nurses, and patients from the earliest stages of development.

6.5. Regulatory and Legal Hurdles: Regulatory bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are still developing frameworks for evaluating and approving AI-based SaMD (Software as a Medical Device). Unlike a drug, an algorithm can continuously learn and change after deployment, posing challenges for ongoing validation ("locked" vs. "adaptive" algorithms). Furthermore, liability is a gray area. If an AI-driven CDS provides an incorrect recommendation that harms a patient, who is responsible—the clinician who followed it, the hospital that implemented it, or the company that developed the algorithm?

6.6. Data Privacy and Security: The use of vast amounts of sensitive patient health information to train and run these algorithms raises significant privacy concerns. Robust cybersecurity measures and strict adherence to regulations like HIPAA (in the U.S.) and GDPR (in Europe) are mandatory.

7. FUTURE DIRECTIONS AND RECOMMENDATIONS

Looking ahead, several technological and methodological advancements promise to further refine AI-powered CDSS for T2D.

7.1. Federated Learning: To address the challenges of data privacy and data siloing, federated learning is a promising paradigm. Instead of moving data to a central server to train a model, the model is sent to the data. The algorithm is trained locally at each participating hospital or clinic, and only the model updates (not the patient data) are sent back to be aggregated into a global model. This allows for collaboration across institutions to build larger, more generalizable models without compromising patient privacy.

7.2. Causal AI: Current predictive models excel at correlation, not causation. They can identify that a certain group of patients has a higher risk, but they cannot definitively say that

a specific intervention will *cause* a better outcome for an individual. Causal AI aims to build models that can reason about cause and effect. A causal CDS could simulate the potential outcomes of different treatment choices for a specific patient, allowing the clinician to choose the intervention with the highest predicted benefit, moving from "what will happen" to "what should we do."

7.3. The Digital Twin: A visionary concept is the "digital twin" of a patient. This would be a dynamic, computational model of an individual's physiology, integrated with their real-time data from wearables and CGMs. Clinicians could use this virtual counterpart to simulate the effects of different medications, diets, or exercise regimens *before* applying them to the patient, enabling truly personalized and risk-free treatment optimization.

7.4. Recommendations for Progress: To realize this future, a multi-pronged approach is needed:

- **For Researchers:** Adopt standardized reporting frameworks (like TRIPOD-AI) for model development and validation. Conduct prospective clinical trials to demonstrate that AI-driven CSS not only predicts accurately but also improves patient outcomes in real-world settings. Focus on developing interpretable and fair models.
- **For Clinicians and Healthcare Systems:** Engage in the co-design process. Foster a culture of "digital literacy" and human-AI collaboration, viewing AI as a tool to augment, not replace, clinical expertise. Invest in the necessary IT infrastructure and data governance.
- **For Policymakers and Regulators:** Develop agile, clear regulatory pathways for adaptive algorithms. Establish clear legal frameworks for liability. Promote policies that encourage data sharing for model development while prioritizing privacy and equity.

8. CONCLUSION

Type 2 Diabetes is a complex, chronic disease that demands a more sophisticated and personalized approach to care than traditional models can provide. The integration of Artificial Intelligence and predictive algorithms into Clinical Decision Support Systems offers a powerful and transformative solution. By harnessing the vast and growing data streams from EHRs, sensors, and patient reports, AI-driven CDSS can evolve from static, rule-based提醒/alerts into dynamic, predictive partners in care. They can stratify risk with unprecedented accuracy, optimize therapeutic choices on an individual basis, automate the screening for devastating complications, and empower patients to take greater control of their health.

However, the path forward is not without significant hurdles. The risks of bias, the opacity of black-box algorithms, the challenges of workflow integration, and the complexities of regulation and privacy must be confronted with diligence, transparency, and a steadfast commitment to patient safety and equity. The ultimate goal is not to replace the clinician but to augment their judgment, providing them with insights distilled from data at a scale and speed beyond human capability. By fostering a collaborative ecosystem of researchers, clinicians, industry, and policymakers, we can responsibly navigate these challenges and usher in a new era of diabetes care that is not merely reactive, but predictive, preventive, personalized, and profoundly more humane.

REFERENCES

1. Ahlqvist, E., Storm, P., Käräjämäki, A., Martinell, M., Dorkhan, M., Carlsson, A., ... & Groop, L. (2018). Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. *The Lancet Diabetes & Endocrinology*, *6*(5), 361-369.
2. Cryer, P. E. (2012). Hypoglycaemia: the limiting factor in the glycaemic management of Type I and Type II diabetes. *Diabetologia*, *55*(9), 2251-2263.
3. Gulshan, V., Peng, L., Coram, M., Stumpe, M. C., Wu, D., Narayanaswamy, A., ... & Webster, D. R. (2016). Development and validation of a deep learning algorithm for detection of diabetic retinopathy in retinal fundus photographs. *JAMA*, *316*(22), 2402-2410.
4. International Diabetes Federation. (2021). *IDF Diabetes Atlas, 10th ed.* Brussels, Belgium: International Diabetes Federation.
5. Khera, A. V., Rasmussen, J., Shifman, D., Furtado, J., Pinto, R. S., Doria, A., ... & Kathiresan, S. (2021). Polygenic prediction of complex traits and the liability to type 2 diabetes. *Nature Genetics*, *53*(7), 1111-1118.
6. Nimri, R., Battelino, T., Laffel, L. M., Danne, T., Biester, T., Kordonouri, O., ... & DAFN consortium. (2020). The DreaMed Advisor: A decision support system for insulin dose titration. *Diabetes Care*, *43*(7), 1540-1547.
7. Phillips, L. S., Branch, W. T., Cook, C. B., Doyle, J. P., El-Kebbi, I. M., Gallina, D. L., ... & Ziemer, D. C. (2001). Clinical inertia. *Annals of Internal Medicine*, *135*(9), 825-834.
8. Van Der Sijs, H., Aarts, J., Vulto, A., & Berg, M. (2006). Overriding of drug safety alerts in computerized physician order entry. *Journal of the American Medical Informatics Association*, *13*(2), 138-147.

9. Zafar, A., Stone, M. A., & Davies, M. J. (2021). Overcoming clinical inertia in the management of type 2 diabetes: a review of the barriers and potential solutions. *Diabetes Therapy*, *12*(8), 1761-1771.